Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.83
-0.04 (-0.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $702.47M in the quarter ending September 30, 2024, with 13.29% growth. This brings the company's revenue in the last twelve months to $2.68B, up 12.32% year-over-year. In the year 2023, Amneal Pharmaceuticals had annual revenue of $2.39B with 8.20% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+12.32%
P/S Ratio
0.85
Revenue / Employee
$341,455
Employees
7,850
Market Cap
2.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AMRX News
- 3 days ago - Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire
- 24 days ago - Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - Business Wire
- 4 weeks ago - Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - Business Wire
- 2 months ago - Amneal to Participate at Upcoming Investor Conferences - Business Wire
- 3 months ago - Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Business Wire
- 3 months ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Amneal Reports Third Quarter 2024 Financial Results - Business Wire
- 4 months ago - Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire